ImmunityBio, Inc.IBRX
ASignal's systematic analysis rates IBRX as Neutral.
Reflects the latest available analysis · analyzed Aug 27, 2026
The case on IBRX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (93.9% YoY)
- High gross margin (99.34%) indicating pricing power
- Current ratio of 5.72x suggests strong liquidity position
- MACD histogram is positive and expanding, indicating strengthening momentum
- Price above SMA20 and SMA50, confirming uptrend
- Negative operating margin (-120.41%) and net margins
- Negative free cash flow (-$186.56M) and operating cash flow (-$281.14M)
- Negative forward P/E (-65.13x) and negative EV/EBITDA (-40.87x) indicating unprofitability
- Price near upper Bollinger Band (8.32) with RSI at 65.15, suggesting overbought conditions
- No Reddit mentions, indicating low retail investor interest or visibility
See the full verdict on IBRX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes IBRX
Most investors never get a second opinion, let alone several. ASignal runs IBRX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.